Use of the oral beta blocker bisoprolol to reduce the rate of exacerbation in people with chronic obstructive pulmonary disease (COPD): a randomised controlled trial (BICS)
DiscussionThe demonstration that bisoprolol reduces the incidence of exacerbations would be relevant not only to patients and clinicians but also to healthcare providers, in the UK and globally.Trial registrationCurrent controlled trialsISRCTN10497306. Registered on 16 August 2018
Source: Trials - Category: Research Source Type: clinical trials
More News: Beta-Blockers | Bisoprolol | Cardiology | Cardiovascular | Chronic Obstructive Pulmonary | Computers | Corticosteroid Therapy | Healthcare Costs | Heart | Heart Disease | Heart Failure | Research | Respiratory Medicine | Smokers | Study